Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Patients with Decompensated Cirrhosis2015년 대한간학회 C형간염 진료 가이드라인 개정, 무엇이 달라졌는가? – 비대상성 간경변증 환자의 치료
- Other Titles
- 2015년 대한간학회 C형간염 진료 가이드라인 개정, 무엇이 달라졌는가? – 비대상성 간경변증 환자의 치료
- Authors
- Gwak, G.Y.
- Issue Date
- Mar-2016
- Publisher
- 대한소화기학회
- Keywords
- Decompensated liver cirrhosis; Direct-acting antiviral agents; Hepatitis C virus
- Citation
- The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, v.67, no.3, pp 137 - 141
- Pages
- 5
- Indexed
- SCOPUS
KCI
- Journal Title
- The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
- Volume
- 67
- Number
- 3
- Start Page
- 137
- End Page
- 141
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/94077
- DOI
- 10.4166/kjg.2016.67.3.137
- ISSN
- 1598-9992
2233-6869
- Abstract
- HCV-related decompensated liver cirrhosis is a life-threatening illness with an average 5-year survival rate of 50%. Because these patients have higher risk of morbidity and mortality including development of hepatocellular carcinoma, the benefits of eradicating the virus may be greater than in those with less-advanced disease. Recently, direct-acting antiviral agents (DAAs) are replacing interferon-based regimens that have serious adverse events and low tolerability in the treatment of HCV infection. Many clinical trials using combination of several DAAs with or without ribavirin are now actively on-going in HCV-related decompensated cirrhosis, and encouraging data are beginning to appear. In this review, recent advances in the treatment of HCV-related decompensated cirrhosis are introduced with special focus on new DAAs.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.